Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Antibodies, Neutralizing: Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.Antibody Affinity: A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.Fluorescent Antibody Technique: Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.Antibodies, Anti-Idiotypic: Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.Binding Sites, Antibody: Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.Antibodies, Neoplasm: Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.HIV Antibodies: Antibodies reactive with HIV ANTIGENS.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Epitopes: Sites on an antigen that interact with specific antibodies.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Antibodies, Protozoan: Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.Antibodies, Antinuclear: Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Antibodies, Fungal: Immunoglobulins produced in a response to FUNGAL ANTIGENS.Neutralization Tests: The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Antigen-Antibody Reactions: The processes triggered by interactions of ANTIBODIES with their ANTIGENS.Antibodies, Bispecific: Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.Mice, Inbred BALB CSkin Neoplasms: Tumors or cancer of the SKIN.Single-Chain Antibodies: A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Antibodies, Blocking: Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Immunoglobulin Fab Fragments: Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.Antibodies, Heterophile: Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.Antibodies, Catalytic: Antibodies that can catalyze a wide variety of chemical reactions. They are characterized by high substrate specificity and share many mechanistic features with enzymes.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Fluorescent Antibody Technique, Indirect: A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Immunoglobulin A: Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.Hybridomas: Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Immune Sera: Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.Lung Neoplasms: Tumors or cancer of the LUNG.Epitope Mapping: Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.Antibodies, Antiphospholipid: Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Cell Line: Established cell cultures that have the potential to propagate indefinitely.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Antigens: Substances that are recognized by the immune system and induce an immune reaction.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Liver Neoplasms: Tumors or cancer of the LIVER.Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.DNA, Neoplasm: DNA present in neoplastic tissue.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Immunization, Passive: Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Immunoassay: A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Immunoglobulin Fragments: Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.Molecular Weight: The sum of the weight of all the atoms in a molecule.Immunoblotting: Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Radioimmunoassay: Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Electrophoresis, Polyacrylamide Gel: Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Colonic Neoplasms: Tumors or cancer of the COLON.Eye Neoplasms: Tumors or cancer of the EYE.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Immunologic Techniques: Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Complement Fixation Tests: Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.Immunoglobulin Variable Region: That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Hemagglutination Tests: Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)Hemagglutination Inhibition Tests: Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.Antibodies, Antineutrophil Cytoplasmic: Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.Nose Neoplasms: Tumors or cancer of the NOSE.Seroepidemiologic Studies: EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Immunoglobulin Idiotypes: Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.Adenoma: A benign epithelial tumor with a glandular organization.Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Neoplasms, Radiation-Induced: Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Uterine Neoplasms: Tumors or cancer of the UTERUS.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Immunoglobulins: Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.Immunosorbent Techniques: Techniques for removal by adsorption and subsequent elution of a specific antibody or antigen using an immunosorbent containing the homologous antigen or antibody.Cattle: Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.Neoplasms, Muscle Tissue: Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.Haptens: Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Antibody Diversity: The phenomenon of immense variability characteristic of ANTIBODIES. It enables the IMMUNE SYSTEM to react specifically against the essentially unlimited kinds of ANTIGENS it encounters. Antibody diversity is accounted for by three main theories: (1) the Germ Line Theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; (2) the Somatic Mutation Theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and (3) the Gene Rearrangement Theory, which holds that antibody diversity is generated by the rearrangement of IMMUNOGLOBULIN VARIABLE REGION gene segments during the differentiation of the ANTIBODY-PRODUCING CELLS.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Peptide Library: A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.Spleen: An encapsulated lymphatic organ through which venous blood filters.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Hepatitis C Antibodies: Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.Mice, Inbred C57BLIsoantibodies: Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.Vascular Neoplasms: Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.Immunoglobulin Isotypes: The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Neoplasms, Adnexal and Skin Appendage: Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.Sweat Gland NeoplasmsAdenocarcinoma: A malignant epithelial tumor with a glandular organization.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Breast Neoplasms: Tumors or cancer of the human BREAST.Hepatitis B Antibodies: Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.Peptide Fragments: Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.Immunodiffusion: Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.Palatal Neoplasms: Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Binding, Competitive: The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.Splenic Neoplasms: Tumors or cancer of the SPLEEN.Neoplasms, Complex and Mixed: Neoplasms composed of more than one type of neoplastic tissue.Species Specificity: The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.Immunity, Maternally-Acquired: Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk.Mandibular Neoplasms: Tumors or cancer of the MANDIBLE.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Insulin Antibodies: Antibodies specific to INSULIN.Complement System Proteins: Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.Recombinant Fusion Proteins: Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.Peptides: Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.Immunoglobulin Heavy Chains: The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.Iodine Radioisotopes: Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.Immunochemistry: Field of chemistry that pertains to immunological phenomena and the study of chemical reactions related to antigen stimulation of tissues. It includes physicochemical interactions between antigens and antibodies.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Autoantigens: Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.Heart Neoplasms: Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.Precipitin Tests: Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.Microscopy, Electron: Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.Stomach Neoplasms: Tumors or cancer of the STOMACH.Tissue Distribution: Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Membrane Proteins: Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.Maxillary Neoplasms: Cancer or tumors of the MAXILLA or upper jaw.Serologic Tests: Diagnostic procedures involving immunoglobulin reactions.Membrane Glycoproteins: Glycoproteins found on the membrane or surface of cells.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Anal Gland Neoplasms: Tumors or cancer of the anal gland.Cloning, Molecular: The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.Antibody-Dependent Cell Cytotoxicity: The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.Kinetics: The rate dynamics in chemical or physical systems.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.Protein Binding: The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Neoplasms, Adipose Tissue: Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.Single-Domain Antibodies: An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.Polysaccharides, Bacterial: Polysaccharides found in bacteria and in capsules thereof.Chromatography, Affinity: A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)

Immune responses to all ErbB family receptors detectable in serum of cancer patients. (1/1721)

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.  (+info)

Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. (2/1721)

p53 alterations are considered to be predictive of poor prognosis in hepatocellular carcinoma (HCC) and may induce a humoral response. Anti-p53 serum antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using purified recombinant human p53 on 130 European HCC patients before treatment and during the clinical course of the disease. p53 immunohistochemistry was performed on tumours from the 52 patients who underwent surgery, and DNA sequencing analysis was initiated when circulating anti-p53 antibodies were detected. Nine (7%) HCC patients had anti-p53 serum antibodies before treatment. During a mean period of 30 months of follow-up, all the negative patients remained negative, even when recurrence was observed. Of the nine positive patients, eight were still positive 12-30 months after surgery. The presence of anti-p53 serum antibodies was correlated neither with mutation of the p53 gene nor the serum alpha-fetoprotein levels and clinicopathological characteristics of the tumours. However, a greater incidence of vascular invasion and accumulation of p53 protein were observed in the tumours of these patients (P<0.03 and P<0.01 respectively) as well as a better survival rate without recurrence (P = 0.05). In conclusion, as was recently shown in pancreatic cancer, anti-p53 serum antibodies may constitute a marker of relative 'good prognosis' in a subgroup of patients exhibiting one or several markers traditionally thought to be of bad prognosis.  (+info)

Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library. (3/1721)

To identify the epitope of the melanoma-associated chondroitin sulfate proteoglycan (MCSP) recognized by the monoclonal antibody (mAb) 763.74, we first expressed random DNA fragments obtained from the complete coding sequence of the MCSP core glycoproteins in phages and selected without success for binders to the murine mAb 763.74. We then used a library of random heptapeptides displayed at the surface of the filamentous M13 phage as fusion protein to the NH2-terminal portion of the minor coat protein III. After three rounds of selection on the bound mAb, several phages displaying related binding peptides were identified, yielding the consensus sequence Val-His-Leu-Asn-Tyr-Glu-His. Competitive ELISA experiments showed that this peptide can be specifically prevented from binding to mAb 763.74 by an anti-idiotypic MK2-23 mouse:human chimeric mAb and by A375 melanoma cells expressing the antigen MCSP. We screened the amino acid sequence of the MCSP molecule for a region of homology to the consensus sequence and found that the amino acid sequence Val-His-Ile-Asn-Ala-His spanning positions 289 and 294 has high homology. Synthetic linear peptides corresponding to the consensus sequence as well as to the MCSP-derived epitope inhibit the binding of mAb 763.74 to the phages displaying the consensus amino acid sequence. Finally, the biotinylated consensus peptide absorbed to streptavidin-microtiter plates can be used for the detection of mAb 763.74 in human serum. These results show clearly that the MCSP epitope defined by mAb 763.74 has been identified.  (+info)

A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. (4/1721)

In this study we performed N-terminal sequence analysis of gp20, a 20 kDa sialoglycoprotein on the human sperm surface previously identified by radiolabelling of the sialic acid residues of sperm surface. We found 100% identity with the N-terminus of CD52, an antigen expressed on almost all human leukocytes. We also show that, like CD52, gp20 behaves as a glycosylphosphatidylinositol (GPI)-anchored protein and that anti-gp20 antiserum reacts with an antigen on leukocytes of the same molecular weight as CD52. Using CAMPATH-1, the monoclonal antibody against CD52, in fluorescent staining of capacitated spermatozoa, Western blot analysis and the zona-free hamster egg penetration test, we found that the effect of this antibody was different from that of our anti-gp20. Western blot analysis revealed a well-defined 20 kDa band with anti-gp20, whereas a 14-20 kDa band was detected with CAMPATH-1. Anti-gp20 stained the equatorial region of the sperm head, whereas CAMPATH-1 stained the tail in immunofluorescence analysis of capacitated spermatozoa. A dose-dependent inhibitory effect was seen with CAMPATH-1, similar to that previously detected with anti-gp20, in a zona-free hamster egg penetration test. However, with CAMPATH-1 agglutination of motile spermatozoa was detected, and this was not present with anti-gp20. This suggests that the epitopes recognized by the two antibodies are different.  (+info)

Adoptive immunotherapy of a Gross virus producing lymphoma and a methylcholanthrene-induced fibrosarcoma in tolerant rats. (5/1721)

Immunological tolerance to Gross virus-specific transplantation antigens in rats given neonatae transfer of donor lymphoid cells beneath the kidney capsule of syngeneic recipient rats. Immune or normal donor cells invariably developed a cell-mediated immune reaction in kidneys of GV-tolerant recipients, presumably against GV antigens present on the surface of recipient lymphoid cells in the kidney. Spleen and lymph node cells from tolerant rats failed to develop a reaction in tolerant recipients, but developed a strong reaction to histoincompatible antigens in the kidneys of semisyngeneic tolerant rats. The immunologically tolerant state in the rats could be broken by adoptive transfer of spleen and lymph node cells from syngeneic rats immunized with GV-induced lymphoma cells. Immunotherapy of a GV-induced and also a GV-infected methylcholanthrene-induced fibrosarcoma growing in tolerant rats was successful when immune spleen and lymph node cells were administered i.p. 3 days after s.c. inoculation of 2 X 10(7) tumor cells in the case of the lymphoma, and 1 day after inoculation of 5 X 10(6) tumor cells in the case of the fibrosarcoma.  (+info)

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. (6/1721)

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is directed against the Lewis-Y antigen, which is expressed on 75% of all breast cancers but is limited in expression on normal tissues. Preclinical xenograft models demonstrated significant antitumor activity, including cures. A randomized phase II design was chosen to estimate the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin. PATIENTS AND METHODS: Patients with measurable metastatic breast cancer and immunohistochemical evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m2 IV over 24 hours or doxorubicin 60 mg/m2 every 3 weeks. Patients were stratified on the basis of prior doxorubicin exposure, visceral disease, and institution. Cross-over to the opposite treatment arm was allowed with progressive or persistently stable disease. RESULTS: Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable. There was one partial response (7%) in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses (44%) in nine assessable patients receiving doxorubicin. No patient experienced a clinically significant hypersensitivity reaction. The toxicities were significantly different between the two treatment groups, with the BR96-doxorubicin conjugate group having limited hematologic toxicity, whereas gastrointestinal toxicities, including marked serum amylase and lipase elevations, nausea, and vomiting with gastritis, were prominent. CONCLUSION: The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer. The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites.  (+info)

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. (7/1721)

PURPOSE: In patients undergoing cytokine therapy, systemically applied interleukin-2 (IL-2) and/or interferon-alpha (IFN-alpha) have been reported to induce thyroid dysfunction as well as thyroid autoantibodies. We analyzed the correlation of thyroid autoimmunity with HLA phenotype, various other autoimmune parameters, and patient survival. PATIENTS AND METHODS: For this purpose, antithyroglobulin autoantibodies, antimicrosomal thyroid autoantibodies, thyroglobulin receptor autoantibodies, thyroid dysfunction, and multiple clinical parameters were determined in 329 unselected patients with metastatic renal cell cancer before and after systemic IL-2 and IFN-alpha2 therapy. For statistical analysis, we used both univariate and multivariate Cox proportional hazards models and the two-tailed Fisher's exact test. RESULTS: Antithyroglobulin autoantibodies and antimicrosomal thyroid autoantibodies were detected in 60 patients (18%); positive autoantibody titers of various other autoimmune parameters were statistically unrelated. The presence of thyroid autoantibodies was correlated with prolonged survival (P<.0001). There was a statistically significant difference in frequencies of HLA-Cw7 expression between thyroid autoantibody-positive and -negative patients (P< or =.05), and the Cw7 expression was associated with prolonged overall survival (P = .009). CONCLUSION: The evaluation of thyroid autoantibodies during cytokine therapy could be a useful prognostic marker for patients with renal cell carcinoma who benefit from cytokine treatment. IL-2- and IFN-alpha2-induced tumor control and prolonged survival may require breaking of immunologic tolerance against self-antigens.  (+info)

Prognostic value of p53 genetic changes in colorectal cancer. (8/1721)

PURPOSE: To explore whether there is a linkage between different mutations in the p53 gene in primary colorectal cancer and the risk of death from colorectal cancer in a large group of patients with long follow-up. We also compared a complementary DNA-based sequencing method and an immunohistochemical (IHC) method for detecting p53 protein overexpression in colorectal cancer. MATERIALS AND METHODS: The entire coding region of the p53 gene was sequenced in 191 frozen tumor samples collected from January 1988 to November 1992. RNA was extracted and synthesized to cDNA. p53 was amplified by the polymerase chain reaction, and the DO-7 monoclonal antibody was used in the IHC assessments. RESULTS: Mutations were detected in 99 samples (52%) from 189 patients. There was a significant relationship between the p53 mutational status and the cancer-specific survival time, with shorter survival time for patients who had p53 mutations than for those who did not (P = .01, log-rank test). Mutations outside the evolutionarily conserved regions were associated with the worst prognosis. Multivariate analysis showed that the presence of p53 mutations was an independent prognostic factor (relative hazard, 1.7, P = .03). There was no significant relationship between overexpression of p53 protein, as determined by IHC analysis, and cancer-specific survival. CONCLUSION: Mutational analyses of the p53 gene, using cDNA sequencing in colorectal cancer, provide useful prognostic information. In addition, cDNA sequencing gives better prognostic information than IHC assessment of p53 protein overexpression.  (+info)

*Monoclonal antibody therapy

Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies ... Antibody-drug conjugates (ADCs) are antibodies linked to one or more drug molecules. Typically when the ADC meets the target ... Four major antibody types that have been developed are murine, chimeric, humanised and human. Antibodies of each type are ... Initial therapeutic antibodies were murine analogues (suffix -omab). These antibodies have: a short half-life in vivo (due to ...

*Pregnancy test

In the 1970s, the discovery of monoclonal antibodies led to the development of the relatively simple and cheap immunoassays, ... and gestational trophoblastic neoplasms.[medical citation needed] Pregnancy tests may be used to determine the viability of a ... These include choriocarcinoma and other germ cell tumors, IgA deficiencies, heterophile antibodies, enterocystoplasties, ...

*Proliferating cell nuclear antigen

... or monoclonal antibody termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic ... PCNA type 1 and type 2 Antibody Patterns". Antibody Patterns.com. Retrieved 2008-04-15. Dan Krotz. "Structure of a clamp-loader ... Imaging of the nuclear distribution of PCNA (via antibody labeling) can be used to distinguish between early, mid and late S ... However, an important limitation of antibodies is that cells need to be fixed leading to potential artifacts. On the other hand ...

*Mycoplasma genitalium

The antibody reactivity was due to a protein never known before, and is chemically responsive to all types of human and ... The protein was identified during investigations on the origin of multiple myeloma, a B-cell hematologic neoplasm. To ... "A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union". Science. 343 (6171): 656-661 ... nonhuman antibodies available. The protein is about 50 kDa in size, and composed of 556 amino acids. Future research must focus ...

*Topoisomerase

... may lead to secondary neoplasms in the patient.[citation needed] Topoisomerase I is the antigen recognized by Anti Scl-70 ... antibodies in scleroderma. There are three main types of topology: Supercoiling Knotting Catenation Outside of the essential ...

*Index of HIV/AIDS-related articles

... neoplasm - nephrotoxic - neuralgia - neurological complications of AIDS - neuropathy - neutralization - neutralizing antibody ... antibodies - antibody-dependent cell-mediated cytotoxicity (ADCC) - antibody-mediated immunity - antifungal medication - ... functional antibody - fungus - fusin - fusion inhibitor - fusion mechanism - fusion peptide GAG - gamma globulin - gamma ... binding antibody - bioavailability - biological response modifiers (BRMs) - biopsy - biotechnology - blinded study - blips - ...

*Paraneoplastic pemphigus

... intraepidermal antibodies as well as along the dermoepidermal junction. Patients with low concentration of antibodies only ... in association with an underlying neoplasm". A study concluded in 2009, summarized in 2010, surrounded the surgical removal of ... Demonstration of certain antibodies in the serum was named as the basis for diagnosis of PNP. This piece labeled PNP as a " ... Specifically, antibodies against envoplakin and periplakin were being investigated. Further use of ELISA testing on these ...

*List of MeSH codes (D12.776)

... antibodies, neoplasm MeSH D12.776.377.715.548.114.248 - antibodies, phospho-specific MeSH D12.776.377.715.548.114.252 - ... antibodies MeSH D12.776.377.715.548.114.071 - antibodies, anti-idiotypic MeSH D12.776.377.715.548.114.107 - antibodies, ... antibodies, bispecific MeSH D12.776.377.715.548.114.143 - antibodies, blocking MeSH D12.776.377.715.548.114.167 - antibodies, ... antibodies, helminth MeSH D12.776.377.715.548.114.191 - antibodies, heterophile MeSH D12.776.377.715.548.114.224 - antibodies, ...

*List of MeSH codes (D12.776.124)

... antibodies, neoplasm MeSH D12.776.124.486.485.114.248 -- antibodies, phospho-specific MeSH D12.776.124.486.485.114.252 -- ... antibodies, neoplasm MeSH D12.776.124.790.651.114.248 -- antibodies, phospho-specific MeSH D12.776.124.790.651.114.252 -- ... antibodies MeSH D12.776.124.486.485.114.071 -- antibodies, anti-idiotypic MeSH D12.776.124.486.485.114.089 -- antibodies, ... antibodies, blocking MeSH D12.776.124.486.485.114.167 -- antibodies, catalytic MeSH D12.776.124.486.485.114.179 -- antibodies, ...

*CD44

Monoclonal antibodies against CD44 variants include bivatuzumab for v6. CD44 is a multistructural and multifunctional cell ... On the contrary, in some neoplasms CD44 upregulation is associated with a favorable outcome. Additionally, in many cases ... Experiments in animals have shown that targeting of CD44 by antibodies, antisense oligonucleotides, and CD44-soluble proteins ... markedly reduces the malignant activities of various neoplasms, stressing the therapeutic potential of anti-CD44 agents. ...

*Immunoglobulin light chain

Only one type of light chain is present in a typical antibody, thus the two light chains of an individual antibody are ... with a highly divergent ratio indicative of neoplasm. The exact normal ratio of kappa to lambda, according to a novel ... The immunoglobulin light chain is the small polypeptide subunit of an antibody (immunoglobulin). A typical antibody is composed ... Monoclonal antibodies Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2001). "Serum reference ...

*Monoclonal

The most common usages of this term are: Monoclonal antibodies: A single hybridoma cell, which by chance includes the ... Monoclonal neoplasms (tumors): A single aberrant cell which has undergone an oncogenic event reproduces itself into a large ... In informal laboratory jargon the monoclonal antibodies isolated from cell culture supernatants of these hybridoma clones ( ... appropriate V(D)J recombination to produce the desired antibody, is cloned to produce a large population of identical cells. ...

*Plasma cell

They secrete high levels of antibodies, ranging from hundreds to thousands of antibodies per second per cell. Unlike their ... Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia and plasma cell leukemia are malignant neoplasms ("cancer") of ... Plasmablasts secrete more antibodies than B cells, but less than plasma cells. They divide rapidly and are still capable of ... Plasma cells can only produce a single kind of antibody in a single class of immunoglobulin. In other words, every B cell is ...

*Thyroid

The most common neoplasm affecting the thyroid gland is a benign adenoma, usually presenting as a painless mass in the neck. ... These antibodies activate the receptor, leading to development of a goitre and symptoms of hyperthyroidism, such as heat ... Lastly, antibodies against components of the thyroid, particularly anti-TPO and anti-thyroglobulin, can be measured. These may ... Occasionally such antibodies block but do not activate the receptor, leading to symptoms associated with hypothyroidism. In ...

*Cathepsin K

"Anti-Cathepsin K Antibody (A5871)"". Antibodies.com online catalog. Antibodies.com Ltd. 2018. Retrieved 16 January 2018. Brömme ... 1 February 2013). ""A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms"". American Journal of Clinical Pathology ... Cathepsin K antibodies are marketed for research into expression of this enyzme by various cells. Merck had a cathepsin K ... link) ""Cathepsin K Antibodies"". Novus Biologicals online catalog. Novus Biologicals, LLC. 2016. Retrieved 2 October 2016. "" ...

*Smooth muscle tissue

Intravascular leiomyomatosis is a benign neoplasm that extends through the veins; angioleiomyoma is a benign neoplasm of the ... Anti-smooth muscle antibodies (ASMA) can be a symptom of an auto-immune disorder, such as hepatitis, cirrhosis, or lupus. ... BBC - baby born with smooth muscle condition has 8 organs transplanted Smooth muscle antibody Stomach smooth muscle identified ... using antibody UIUC Histology Subject 265 Histology at KUMC muscular-muscle08 "Smooth Muscle" Histology image: 21701ooa - ...

*Clone (cell biology)

Another important area where one can talk of "clones" of cells is neoplasms. Many of the tumors derive from one (sufficiently) ... These terms are most commonly used in context of antibodies or immunocytes. This concept of clone assumes importance as all the ... The B cells in the body have two important phenotypes (functional forms) -- the antibody secreting, terminally differentiated ( ... Clone (B-cell biology) Cloning List of animals that have been cloned Polyclonal antibodies Polyclonal response "Clone ...

*BALB/c

... most commonly reticular neoplasms, lung tumours, and renal tumours. Most substrains have a "long reproductive life-span", are ... an important process for the production of monoclonal antibodies. They are also reported as having a "low mammary tumour ...

*Autoimmune autonomic ganglionopathy

Where an underlying neoplasm is the cause, treatment of this condition is indicated in order to reduce progression of symptoms ... If the AAG is paraneoplastic, they have a form of cancer, and their immune system has produced paraneoplastic antibodies in ... Additionally, a blood test showing high levels of the antibody ganglionic nicotenic acetylcholine receptor (gAChr) occur in ... Paola Sandroni & Phillip A. Low (2009). "Other Autonomic Neuropathies Associated with Ganglionic Antibody". Autonomic ...

*Milatuzumab

A Phase I study of Milatuzumab, a humanized anti-CD74 antibody, and Veltuzumab, a humanized anti-CD20 antibody, in patients ... CD74: a new candidate target for the immunotherapy of B-cell neoplasms. R. Stein, M.J. Mattes, T.M. Cardillo, H.J. Hansen, C.H ... Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. P. Sapra, R. Stein, J ... hLL1-Dox Milatuzumab has been linked to doxorubicin to form an antibody-drug conjugate or ADC (known as hLL1-Dox or IMMU-110) ...

*Radioimmunotherapy

By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to ... The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells ... Antibody-targeted radiation cancer therapy. Nature Rev Drug Discovery 2004; 3:488-98. FIbritumomab Tiuxetan (Zevalin™) ...

*Immunoproliferative disorder

... s, also known as immunoproliferative diseases or immunoproliferative neoplasms, are disorders of ... also known as antibodies). These disorders are subdivided into three main classes, which are lymphoproliferative disorders, ...

*Autoimmune hemolytic anemia

Classification of the antibodies is based on their activity at different temperatures and their etiology. Antibodies with high ... Less common causes of warm-type AIHA include neoplasms other than lymphoid, and infection. Secondary cold type AIHA is also ... AIHA can be caused by a number of different classes of antibody, with IgG and IgM antibodies being the main causative classes. ... Usually, the antibody becomes active when it reaches the limbs, at which point it opsonizes RBCs. When these RBCs return to ...

*NS0 cell

Development of murine neoplasms started with work with the BALB/c mice to isolate the IgG1 secreting MOPC21 tumor. From this ... Several therapeutic antibody products are produced using the NS0 cell line including daclizumab and eculizumab. Barnes, LM; ... Galfrè, G; Milstein, C (1981). "Preparation of monoclonal antibodies: strategies and procedures". Methods in Enzymology. 73 (Pt ... they are naturally antibody producing suspension cells. Gene amplication is typically performed using GS-transfected NS0 cells ...

*Lloyd J. Old

Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study with monoclonal antibody A33. ... Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810-11813. ... Of the monoclonal antibodies developed in Dr. Old's laboratory, thirteen have been licensed and seven are in clinical trials. ... the anti-EGFr antibody Hu806, which Abbott Laboratories acquired exclusive world-wide rights to develop in a major licensing ...

*List of diseases (C)

Colavita-Kozlowski syndrome Cold agglutination syndrome Cold agglutinin disease Cold antibody hemolytic anemia Cold contact ... Carrington syndrome Cartilage-hair hypoplasia Cartilage hair hypoplasia like syndrome Cartilaginous neoplasms Cartwright-Nelson ... hypoxia Cerebral malformations hypertrichosis claw hands Cerebral palsy Cerebral thrombosis Cerebral ventricle neoplasms ... Choriocarcinoma Chorioretinitis Chorioretinopathy dominant form microcephaly Choroid plexus cyst Choroid plexus neoplasms ...
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced
Open label multicenter, two-step, non-randomized (pilot) study to analyze the safety of 4 cycles of 3-day 40mg/m2 oral fludarabine with simultaneous thrice weekly application of 30mg alemtuzumab s.c. in patients with B-CLL disease in 1st and 2nd relapse after any primary treatment or with disease refractory to any therapy in 1st or 2nd line (including Fludarabine, ). This regimen is preceded by an escalation phase with 3-10-30 mg of alemtuzumab s.c.. After the first phase (completed treatment of 7 patients) an interim analysis of safety and efficacy will be performed. In case of a sufficient risk benefit assessment followed by the enrollment of further 21 patients. Final analysis of safety and preliminary efficacy will be based on all patients enrolled. ...
Every participant had received active treatment; there was no placebo. Participants who qualified were randomly assigned to treatment with either alemtuzumab or SC interferon beta-1a at a 2:1 ratio (that is, 2 given alemtuzumab for every 1 given interferon beta-1a). Alemtuzumab was administered in two annual courses, once at the beginning of the study and again 1 year later. Interferon beta-1a was self-injected 3 times per week for 2 years. All participants were required to return to their study site every 3 months for neurologic assessment. In addition, safety-related laboratory tests were performed at least monthly. Participation in this study ended 2 years after the start of treatment for each participant. Additionally, participants who received alemtuzumab might be followed in CAMMS03409 (NCT00930553) an extension study for safety and efficacy assessments. Participants who received interferon beta-1a and completed 2 years on study might be eligible to receive alemtuzumab on the extension ...
Alemtuzumab is used in the treatment of blood cancer (chronic lymphocytic leukemia),multiple sclerosis (ms).get complete information about alemtuzumab including usage, side effects, drug interaction, expert advice along with medicines associated with alemtuzumab at 1mg.com
In an analysis of in periods of yore unpublished position III data, U.K. researchers broadcast a oversized, speedy repopulation of a subset of B waste times without vigorous T-cell contribution in patients with multiple sclerosis (MS) enquired with alemtuzumab (Lemtrada), which rule have authored an environment for ancillary autoimmune sickness.. Pumping lymphocyte reconstitution subject-matter from the cardinal Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I and II (CARE-MS I and II) readings, Klaus Schmierer, PhD, FRCP, of Ruler Mary University of London, and joins found that alemtuzumab depleted CD4 T foot-draggings by more than 95%, off regulatory areas and CD8 T cells, which corpsed affectionately deeper testimonial levels globally in the trials. Although the fussy also initially depleted CD19 B corrals by more than 85%, new B apartments distended by 180% and transmuted to season B chambers as a remainder straightaway. These interchanges were associated with the armada ...
CAMPATH (Alemtuzumab) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Horwitz described a different approach to replacing CHOP: He cited a small Phase II study that took what he said was a quite different but very logical tack with a regimen of cisplatin, etoposide, gemcitabine, and prednisone (Cancer 2013;15:119:371-379). Even so, disappointingly, the two-year overall survival rate was only 30 percent, and median overall survival was 17 months. "I dont think this strategy will be going forward," he said.. Horwitz also discussed adding an antibody to CHOP, the CD52 antibody alemtuzumab, which he said some thought might be a "recapitulated R-CHOP" in B-cell lymphoma: One trial of alemtuzumab at 30 mg plus the CHOP-24 regimen for eight cycles (Blood 2007;110:2316-2323) produced a failure-free survival rate of 48 percent and an overall survival rate of 53 percent at two years, but the toxicities included a 17 percent rate of Grade 4 infections. A more recent study, of CHOP-14 with alemtuzumab also saw a two-year overall survival rate of 55 percent, but at two years, ...
Id like to share with you that I received alemtuzumab (Campath trade name) in the hospital 26.04. - 30/04/2011 under the program CARE MS II extension study. Side effects of alemtuzumab infusions continue after I get tired, the most troublesome ...
Mouse monoclonal CD13 antibody [CC81] validated for Flow Cyt and tested in Cow. Immunogen corresponding to tissue, cells or virus
Mouse monoclonal WC1 antibody [CC101] validated for IP, IHC, Flow Cyt and tested in Cow and Pig. Immunogen corresponding to tissue, cells or virus
CD1w3 antibody [CC43] for FACS, IP. Anti-CD1w3 mAb (GTX42307) is tested in Goat, Sheep, Bovine, Sheep samples. 100% Ab-Assurance.
Wc1 antibody [CC15] (FITC) (CD163 molecule-like 1) for FACS. Anti-Wc1 mAb (GTX43329) is tested in Goat, Sheep, Bovine, Sheep samples. 100% Ab-Assurance.
1AD9: VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs.
1AD0: VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs.
I was in the CAMMS323 trial and I received Campath (although I still do not know the dosage). I was only diagnosed with RRMS for one year and 2 months before going into the trial. I am currently at month ...
Learn ways to provide support to your loved ones with relapsing MS, hear advice from other Care Partners, and see what Care Partners mean to MS patients.
引用Abcams Anti-p38抗体[M138] (ab31828)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
p107兔多克隆抗体(ab90507)可与人样本反应并经WB实验严格验证。中国75%以上现货,所有产品均提供质保服务,可通过电话、电邮或微信获得本地专属技术支持。
A 64-year-old woman, with unremarkable previous medical history, was diagnosed with T cell prolymphocytic leukemia in 2006. She received alemtuzumab (30 mg subcutaneously thrice weekly) as first line chemotherapy; combined therapy of valaciclovir and trimethoprim-sulfamethoxazole, for anti-infective prophylaxis, was initiated simultaneously. Before institution of alemtuzumab therapy, full blood cell count disclosed the following: hemoglobin 12.7 g/dL, white blood cell count 88×109/L (absolute neutrophil count: 8.5×109/L, lymphocyte: 79.5×109/L, platelets: 400,000/mm3). Two days after the 9th alemtuzumab injection, the patient exhibited an asymptomatic reactivation of cytomegalovirus (CMV) infection; she was given valganciclovir therapy for 21 days.. Three days after the 16th alemtuzumab injection, she was admitted with a 2-day history of abdominal pain. On admission, the patient was febrile (38°5C); physical examination showed a tenderness in the appendicular area. Laboratory findings ...
The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal antibody alemtuzumab for high-risk chronic lymphocytic leukemia, defined as at least 1 of the following: unmutated immunoglobulin heavy chain genes, deletion 17p or 11q, or trisomy 12. Fit patients were randomized to receive either 6 28-day cycles of oral FC chemotherapy (days 1 through 3: fludarabine 40 mg/m(2) per day and cyclophosphamide 250 mg/m(2) per day: n = 139) or FC plus subcutaneous alemtuzumab 30 mg day 1 (FCA, n = 133). FCA prolonged the primary end point, progression-free survival (3-year progression-free survival 53 vs 37%, P = .01), but not the secondary end point, overall survival (OS). However, a post hoc analysis showed that FCA increased OS in patients younger than 65 years (3-year OS 85% vs 76%, P = .035). FCA also increased the overall response rate (88 vs 78%, P = .036), and the bone marrow minimal residual ...
Recent clinical outcomes and subsequent approvals of anti-CTLA-4 and anti-PD-1 checkpoint blockade antibodies, which mitigate inhibitory signaling that decreases antitumor T cell responses, have ignited extraordinarily broad efforts to develop the potential of cancer immunotherapy (Pardoll, 2012; Topalian et al., 2015). Unlike strategies that typically elicit antitumor responses of limited duration and nearly inevitable treatment resistance, immunotherapeutics can achieve durable and long-lasting antitumor responses in a minority of patients with advanced disease (Sharma and Allison, 2015). To build upon this success, combination immunotherapies are a next logical step (Gajewski et al., 2013; Spranger and Gajewski, 2013).. One such approach combines a tumor-specific antibody to drive antibody-dependent cell-mediated cytotoxicity (ADCC) through neutrophil- and eosinophil-mediated attack and an extended serum half-life IL-2 fusion to activate CD8+ T cells and NK cells. However, this strategy is ...
Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between 1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant delays in immune reconstitution. Here we report |20 years of follow-up data from this unique cohort. Surviving alemtuzumab recipients were age, sex and disease duration matched with RA controls. Updated mortality and morbidity data were collected for alemtuzumab recipients. For both groups antigenic responses were assessed following influenza, Pneumovax II and combined diphtheria/tetanus/poliovirus vaccines. Circulating cytokines and lymphocyte subsets were also quantified. Of 16 surviving alemtuzumab recipients, 13 were recruited: 9 recipients underwent a full clinical assessment and 4 had case notes review only. Since our last review 10 patients had died from causes of death consistent with long-standing RA, and no suggestion of compromised immune function. Compared with controls the alemtuzumab cohort had
Nishioka, K; Irie, R F.; Kawana, T; and Takeuchi, S, "Immunological studies on mouse mammary tumors. Iii. Surface antigens reacting with tumor-specific antibodies in immune adherence." (1969). Subject Strain Bibliography 1969. 1210 ...
In a prospective phase III study in Germany,[155] patients were randomly allocated either no treatment or alemtuzumab 30 mg intravenously three times a week for 12 weeks, beginning a median of 67 days after the last dose of induction chemotherapy (fludarabine with or without cyclophosphamide). Although recruitment to this trial was halted at 21 patients because of severe infections in the alemtuzumab group, those allocated alemtuzumab had significantly longer progression-free survival than those assigned no treatment. Using a very sensitive PCR-based assay with sequence-specific primers to detect minimal residual disease, five of six patients tested became negative for minimal residual disease. Findings of a phase II study156 of alemtuzumab given in doses of 10 mg subcutaneously three times a week for 6 weeks, beginning not less than 8 weeks after discontinuation of fludarabine induction chemotherapy, proved that this regimen was safe and able to turn partial remissions into complete remissions. ...
Alemtuzumab (marketed as Campath or Campath-1H) is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL) and T-cell lymphoma. Alemtuzumab targets CD52, a protein present on
1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnol 2005; 23: 1147-1157. 2. Klener P, Klener P jr. Nová protinádorová léčiva a léčebné strategie v onkologii Grada Publishing a.s. Praha, 2010. 3. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Natur Rev 2010; 10: 317-327. 4. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkinęs lymphoma. Drugs 2007; 67: 333-350. 5. Belada D. Monoklonální protilátky v léčbě lymfomů. Remedia 2008; 6: 416.423 6. Castillo J, Winer E, Quinsberry O. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36: 755-768. 7. Wierda WG, Kipps TJ, Keatimg MJ, et al. Self-administered. subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011; 117: 116-124. 8. Khubchandani S, Czuczman MS, Hernandes-Ilizalituri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of ...
3992 Alemtuzumab (Campath) is a humanized monoclonal antibody directed against the cell surface CD52 antigen that is expressed on the surface of normal and malignant B and T lymphocytes as well as NK cells and macrophages. Although Campath is currently approved for the treatment of B-cell chronic lymphocytic leukemia, the exact mechanism through which Campath mediates its effects has not been fully characterized. We are currently exploring the activity and mechanism of action of Campath in a transgenic mouse that expresses human CD52 under the control of the human CD52 promoter. Similar to humans, expression of human CD52 in these mice can be detected on T and B cells as well as macrophages and NK-cells. We have previously reported that Campath mediated depletion of lymphocytes occurs in a dose and time-dependent manner in the peripheral blood and lymphoid organs of the transgenic mice. Similar results have now been observed with other cell types including both macrophages and NK-cells. To ...
The right thing to do is to is to figure out how to prevent MS in future generations. Forget the DMTs and trials into progressive MS; lets just start from a clean slate. Its unfortunate that we have MS but lets bite the bullet and shift our focus on newborns. Lets make them vitamin D replete. Let us be the last generation to have lived and died with MS. Weve had our moment. Lets accept our fate and live with it rather than drugging ourselves with crap our bodies cant handle. The only reason a MSer will run the risk of taking alemtuzumab is because of desperation. Desperate people are always living in danger. MS can be prevented but its dangerous to think that modern toxins will, somehow, cure it ...
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without h
View: Main AbID Search Nested - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;}tr{ -webkit-transition: all .35s ease-in-out; /* Safari 3.1 to 6.0 */ transition: all .35s ease-in-out; } /* ----------------------------------------- */ /* View: Main AbID Search Nested - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;} /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: ProductsInAntibodyTbl - start */ /* ----------------------------------------- */ a.productappearance{ display:inline-block; font-size:80%; padding:3px; background:gray; color:white!important; ...
View: Main AbID Search Nested - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;}tr{ -webkit-transition: all .35s ease-in-out; /* Safari 3.1 to 6.0 */ transition: all .35s ease-in-out; } /* ----------------------------------------- */ /* View: Main AbID Search Nested - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - start */ /* ----------------------------------------- */ .entry-content thead th a {padding:0!important;} /* ----------------------------------------- */ /* View: List of Antibodies from Antibody ID Ecomm - end */ /* ----------------------------------------- */ /* ----------------------------------------- */ /* View: ProductsInAntibodyTbl - start */ /* ----------------------------------------- */ a.productappearance{ display:inline-block; font-size:80%; padding:3px; background:gray; color:white!important; ...
Unfortunately, there is no cure for multiple sclerosis, however, there are several different options for treating the condition. Find out about specialists who treat the disease and forms of treatment... ...
Alemtuzumab is a highly effective drug for multiple sclerosis, approved in more than 60 countries and used by more than 12,000 patients worldwide.
... (alemtuzumab) - IV infusion given over the course of 5 consecutive days, followed 1 year later with a 3 day consecutive course
... (alemtuzumab) - IV infusion given over the course of 5 consecutive days, followed 1 year later with a 3 day consecutive course
P2X1兔多克隆抗体(ab74058)可与人样本反应并经WB, IHC实验严格验证。中国75%以上现货,所有产品均提供质保服务,可通过电话、电邮或微信获得本地专属技术支持。
CAMPATH-1 (CDw52) antibodies recognize a very small lipid-anchored glycoprotein that is expressed on the surface of human lymphocytes. They are remarkably lytic with human complement. In addition, CAMPATH-1G (rat IgG2b) and CAMPATH-1H (human IgG1) bind to human Fc receptors and are very effective for cell lysis in vivo. CAMPATH-1M (rat IgM) and CAMPATH-1G have been used to control GVHD and graft rejection in bone marrow transplantation by depletion of the T cells of the donor and recipient. Depletion of donor T cells alone gave excellent control of GVHD but up to 20% of the patients transplanted from HLA-matched siblings, and 51% of those transplanted from nonsibling donors, experienced graft failure caused by immunological rejection. Graft rejection could be partly overcome by additional immunosuppression either with CsA or total lymphoid irradiation (TLI). More effective was the use of CAMPATH-1G in vivo to deplete residual host lymphocytes. Preliminary results from current protocols of antibody
Colorful World of Quantum Dots. A few imaging applications using quantum dots (QDs) will be introduced, which will cover from visible to infrared(IR) for the wavelengths and from cellular super-resolution to whole body in vivo imaging for the object scale. (1) QDs were conjugated to tumor-specific antibodies(Abs) with zwitterionic surface coating to reduce nonspecific bindings. The Ab-QD probes were used to diagnose tumors for sectioned mouse tissues, fresh mouse colons stained ex vivo and in vivo, and also for fresh human colon adenoma tissues. The probes successfully detected not only cancers that are readily discernible by bare eyes but also hyperplasia and adenoma regions. Multiplexed QD, spray-and-wash, and endoscopy approach provided a significant advantage for detecting small or flat tumors that may be missed by conventional endoscopic examinations. QD-Ab probe was also used in conjunction with a ratiometric fluorescent molecular probe, cresyl violet-glutamic acid derivative, that ...
Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogramming effects on immune cell composition resulting in the restoration of tolerogenic networks. Alemtuzumab has proven high efficacy in clinical phase II and III trials, where interferon β-1a was used as active comparator. However, alemtuzumab is associated with frequent and considerable risks. Most importantly secondary autoimmune disease affects 30%-40% of patients, predominantly impairing thyroid function. Extensive monitoring and early intervention allow for an appropriate risk management. However, new and reliable biomarkers for individual risk stratification and treatment response to improve patient selection and therapy guidance are a significant unmet need. Only a deeper understanding of the
Mechanism of Action Alemtuzumab (Campath-1H) is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (,95%) normal lymphocytes, and T-cell & B-cell lymphoma cells. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and antitumour T-cell activity. Alemtuzumab has been used for chronic lymphocytic leukemia, low grade lymphomas and other non-cancerous indications.. ...
Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymph
Official pharmaceutical website with information regarding treatment for B-cell chronic lymphocytic leukemia for patients and health professionals. ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
We show that in the first year the occurrence before the next infusion is very small, although not in the paper I have reasonable evidence that at least one out of about 400 people did not respond well to the second cycle because of this. However if you need a third cycle I suspect the risk of the drug not working well is increased (thirty fold) as and so you need to look at your bloods to ensure the drug is working. Genzyme have the data to know how small that risk is, they need to be open about this and this paper will help in that process. If the drug isnt you need to switch.. Delete ...
LEMTRADA®, because of its risks, is generally for relapsing MS patients who have tried 2 or more MS medicines that didnt work well enough.
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Alemtuzumab belongs to the class of medications called selective immunomodulators. It is used to treat adults with relapsing remitting multiple sclerosis (RRMS) who are experiencing an active episode of RRMS and for whom other treatments have not been effective.
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab109185 交差種: Hu 適用: WB,IP,IHC-P,Flow Cyt,ICC/IF
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab92741 交差種: Ms,Rat 適用: WB,IHC-P
Alemtuzumab is a highly efficacious therapy used in the treatment of multiple sclerosis (MS), but uncoupling of T and B cell repopulation during immune reconstitution associates with an increasing range of secondary B cell-mediated autoimmune complications. A 34-year-old woman developed Graves disease 11 months following an initial course of alemtuzumab treatment for MS. Nine months following the second treatment with alemtuzumab, the patient presented with spontaneous intramuscular and subcutaneous haemorrhage due to development of an inhibitory autoantibody to coagulation factor VIII. Acquired haemophilia A (AHA) is an extremely rare complication in patients treated with alemtuzumab. Treatment with rituximab may induce a rapid remission of AHA; however, the patients high John Cunningham virus (JCV) antibody index and alemtuzumab-induced T cell lymphopenia may lead to an increased risk of progressive multifocal leucoencephalopathy, a potential complication which was unacceptable to the ...
Background: Canine hemangiosarcoma is a common and highly aggressive tumor of blood vessels that is often fatal. At diagnosis most dogs have evidence of metastatic disease and despite chemotherapy, survival times rarely exceed 6 months. New approaches to the treatment of this disease are needed. The use of monoclonal antibodies and antibody fragments to directly target different tumors has shown promise in clinical trials in man. Objective: This project aims to use a new canine synthetic antibody system to target the tumor and deliver cytotoxic agents directly to both primary and metastatic lesions. Using advanced molecular techniques, the researchers intend to review antibody responses that dogs with hemangiosarcoma may make against their own tumors and use these as a template to generate canine antibody fragments that specifically recognize tumor particles. Tumor-specific antibody fragments will be linked to an exotoxin and evaluated for their ability to kill canine hemangiosarcoma cells in vitro.
This grant will support novel use of a vaccine adjuvant developed by Immune Design Corporation as a cancer therapeutic for Merkel cell carcinoma (MCC). MCC often occurs in the skin, presenting the opportunity to inject adjuvant directly into the tumor. The adjuvant, which will be tested in 10 MCC patients, is expected to recruit immune cells to the tumor to assist the patients own immune system in attacking the cancer. Immune therapies with antibodies have had some recent spectacular successes, and although this is a different approach (no tumor-specific antibodies will be injected), activating the patients immune system shows promise and is generally safer and better tolerated than traditional chemotherapy. Only about 1,600 patients per year develop MCC, but the University of Washington is a center that attracts both in-state and out-of-state patients, and the therapy may ultimately be applicable to other cancers.. Collaborating organizations: Fred Hutchinson Cancer Research Center, Immune ...
London, UK, 26 September 2007: BTG plc (LSE: BGC), the life sciences company, today announces that its licensee, Genzyme Corporation, and Bayer Schering Pharma AG have initiated a pivotal phase III trial of Campath® (alemtuzumab) as a treatment for multiple sclerosis. This follows the announcement of 20 September that Campath® had been approved as a first-line treatment for B-cell chronic lymphocytic leukaemia.. Louise Makin, BTGs CEO, commented: "We are excited by the prospects of Campath in multiple sclerosis and delighted that the pivotal phase III trials are under way. If the excellent results from the phase II trials are reproduced, patients will have a new treatment option that has the potential to be much more efficacious than any other existing treatment.". The full text of Genzymes announcement follows.. "Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis. Date: September 26, 2007. Genzyme Corporation ...
Campath-1H is a humanized monoclonal antibody targeted against the CDw52 membrane antigen of lymphocytes, which causes complement and antibody-dependent cell-mediated cytotoxicity. Campath-1H has...
Introduction: DC-rIL-2-VMO, an allogeneic cellular melanoma vaccine consisting of five melanoma cell lines, a recombinant vaccinia virus encoding for IL-2, as well as dendritic cells, has previously been shown to generate a potent cellular response in murine tumor models. We now demonstrate that this vaccine also has the capacity to generate a sustained humoral response in vitro.. Methods: To detect anti-tumor antibodies in pre- and post-vaccinated melanoma patients sera, a mixed hemadsorption assay (MHA) was used. The binding of human antibody from diluted patients sera (1:05, 1:15 and 1:45) to cultured melanoma cells (Mel-2, Mel V, GLM-2 and KFM cells) was determined as indicator cells, sheep red blood cells (SRBC) coated sequentially with mouse anti-SRBC sera, goat sera against mouse sera, and mouse anti-human IgG sera to detect binding of human anti-melanoma antibodies.. Results: Out of four patients evaluated with Stage IIIA-C and Stage IV resected with no evaluable disease (NED), three ...
About 6 months ago one of my patients, a 34-year woman, with rapidly involving severe MS failed alemtuzumab therapy with a breakthrough spinal cord relapse at ~7 months post her second course of alemtuzumab. As we dont have funding in place in the NHS to give a 3rd course of alemtuzumab we had to consider other options. One of the options included HSCT (she was eligible under our the London AHSCT guidelines), however, when she was informed that the chances of her becoming infertile from the cyclophosphamide were over 40% she declined HSCT. That is the problem with cyclophosphamide; in high-doses it is seriously toxic to both the ovaries and testes and patients have to bank eggs (oocytes) and sperm. Cyclophosphamide is a potent immunosuppression so infections are a major risk. It also causes hair loss, mucositis, enteritis, hemorrhagic cystitis, nausea, vomiting, etc. I did my house job in a haemoncology ward and have personal experience with both allogeneic and autologous bone marrow ...
This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body
The population-based mortality of melanoma has increased dramatically, ∼4% per year in the United States and ,20-fold since 1930, with ,60,000 new cases and ,8,000 deaths by 2009. In terms of numbers, another neuroectodermal tumor, small cell lung cancer, far exceeds melanoma as cause of death (25,000 per year) and is also GD3+ and a suitable target of therapy and for which no effective treatment currently exists (24). Further GD3+ malignancies include glioma, neuroblastoma, and others that could similarly be attacked by this strategy (3).. There is no standard curative treatment for advanced melanoma, which remains poorly responsive to chemotherapy, biotherapy, and radiotherapy (25). However, melanoma is one of the most immunoresponsive of human cancers and has served as prototype for the development of a number of different immunotherapies (26). Immunotherapy of melanoma typically uses one or several strategies: antitumor antibody, TILs, cytokines, vaccines (peptide and dendritic cell), and ...
Monoclonal antibody therapy targeted therapy that can be used to treat colon cancer and other cancers. Find out about how it works and side effects.
Alemtuzumab to Treat Severe Aplastic Anemia This study is currently recruiting participants. Verified April 2012 by National Institutes of Health Clinical…
Health,... Results suggest new hope for patients with refractory chronic l...BARCELONA SPAIN June 12 ---ILEXTM Oncology Inc. (NASDAQ: ILXO) and... The results of this trial are encouraging said Dr. Keating Associ...The non-comparative trial involved 93 previously treated patients wh...,ILEX,Oncology,&,LeukoSite,report,results,from,pivotal,Phase,II,CAMPATH,(R),trial;,Results,suggest,new,hope,for,refractory,chronic,lymphocytic,leukemia,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
A drug used to treat B-cell chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. Alemtuzumab binds to a protein called CD52, which is found on some types of immune cells and cancer cells. This may help the immune system kill cancer cells. Alemtuzumab is a type of monoclonal antibody. Also called Campath ...
But tomorrow. Tomorrow began yesterday. Yesterday, my white blood cell count was too low for me to receive my Campath injection. I received a hydration pack and the rG-CSF shot to help my counts come back up. I also saw my doctor. She told me that everyone is a little worried about me. Apparently, my reactions have gone above and beyond what is normal for this injection. My white cell count was not supposed to drop, especially into the neutropenia levels. So I was sent away from clinic with instructions to keep giving myself the growth-factor shot, drink lots of water, and come back on Friday. Today, Thursday, I grudgingly went to my volunteer job. Grudgingly because, basically, I felt like... well, I didnt feel well. Anywhoo, so I got home from work, ate some foodings, and settled down for my Thursday-night primetime. About 1/4 of the way into Greys Anatomy, my doctor called. And she posed to me this option: I can choose to stop the Campath injections. The doctors are worried about how badly ...
Could you explain to me alemtuzumab used with fludarabine? This is my fifth relapse, and the preceding is the protocol my doctor is going to use.
Abstract: Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21-53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV-DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV-DNA seronegative, anti-HBs and anti-HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two ...
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of active relapsing-remitting (RR) multiple sclerosis (MS). Alemtuzumab induces a rapid and prolonged depletion of lymphocytes from the circulation, which results in a profound immuno-suppression status followed by an immune reconstitution phase. Secondary to reconstitution autoimmune diseases represent the most common side effect of Alemtuzumab treatment. Among them, Graves disease (GD) is the most frequent one with an estimated prevalence ranging from 16.7 to 41.0 % of MS patients receiving Alemtuzumab. Thyrotropin (TSH) receptor (R)-reactive B cells are typically observed in GD and eventually present this autoantigen to T-cells, which, in turn, secrete several pro-inflammatory cytokines and chemokines. Given that reconstitution autoimmunity is more frequently characterized by autoantibody-mediated diseases rather than by destructive Th1-mediated disorders, it is not surprising that GD is the most commonly reported
http://www.northeastern.edu/research/centers/center-for-pharmaceutical-biotechnology-and-nanomedicine/ View Website » The Center for Pharmaceutical Biotechnology and Nanomedicine is a recently organized research unit aiming to perform studies on the border between two fast growing scientific areas, Biotechnology and Nanomedicine. The missions of the Center include: 1. Intensive research in such areas as Nanomedicine (pharmaceutical nanocarriers with controllable properties for delivery and targeting of water-insoluble drugs, DNA, and diagnostic agents to various disease sites); Intracellular Drug Delivery (the use of cell penetrating peptides for delivery of drugs and DNA directly into the cell cytoplasm bypassing the endocytic pathway and increasing the efficiency of therapies); Experimental Cancer Immunotherapy (the research in the area of tumor-specific antibodies and the use of these antibodies for specific delivery of drugs and diagnostic agents to tumors); Combination Therapy of Cancer ...
BACKGROUND: Leukocyte depletion at the time of transplantation with alemtuzumab (Campath-1H) has been demonstrated to be a potential strategy for reducing long-term exposure to immunosuppressive drugs. Although the impact of alemtuzumab treatment on the immune system has been explored, the effects of long-term immunosuppressive therapy in alemtuzumab-treated patients still need to be elucidated. METHODS: T-regulatory cells and Th1/Th17 responses were assessed by flow cytometry and real-time polymerase chain reaction more than 4 years after transplantation in 10 kidney recipients treated with alemtuzumab induction. Seven patients were converted to sirolimus monotherapy at 12 months posttransplant, whereas the remaining three patients with history of graft rejection were treated with sirolimus and mycophenolate mofetil. In addition, we sorted and expanded interleukin (IL)-17A-producing CCR6CD4 T cells and assessed their susceptibility to suppression by regulatory T (Treg) cells in in vitro suppression
Monoclonal Antibody (mAB) Therapy is a type of immunotherapy. It employs specific antibodies to target cancer cells for removal from the body. This type of therapy relies on the bodys own immune system to fight the cancer, rather than attacking the cells with damaging chemotherapy and radiation.. To understand how this therapy works, you must understand what antigens and antibodies are. Antigens are cell markers that are produced in every type of cell - the cells of your body, bacteria, and viruses. These markers are different in every cell type, so your body can tell them apart. Antibodies are designed to bind to antigens, like fitting two puzzle pieces together. Monoclonal antibodies are large groups of antibodies that only bind to one antigen.. In monoclonal antibody therapy, doctors inject patients with antibodies that bind to the antigens on cancer cells. In this way, they are "tagging" the bad cells. When cells are tagged with these antibodies, they are marked for removal by immune cells. ...
The goal of this clinical research study is to determine the effectiveness of alemtuzumab in patients with aplastic anemia, MDS, or T-Cell large granular lymphocytic leukemia. The safety of alemtuzumab will also be studied.
Alemtuzumab / LEMTRADA is a monoclonal antibody used in treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) & T-cell lymphoma.
Alemtuzumab / LEMTRADA is a monoclonal antibody used in treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) & T-cell lymphoma.
Norovirus infection can occur in the setting of alemtuzumab treatment and should be included in the differential diagnoses of acute and chronic diarrhea.
Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for the treatment of active relapsing-remitting MS. Alemtuzumab, administered intravenously, was shown to improve relapse rate versus subcutaneous interferon beta-1a in patients who were treatment-naive (CAMMS223 and CARE-MS I) or had relapsed on prior therapy (CARE-MS II), and to reduce sustained accumulation of disability (CAMMS223 and CARE-MS II ...
Read I Am Wonderfully Me Positive Affirmations for Me! Volume 3 by Audrey Tait with Rakuten Kobo. Where Is Your Focus in Life? Is it on others or on yourself? Do you look after yourself first, before others, so that yo...
NY-ESO-1 is a human tumor antigen of the cancer/testis family. It is highly expressed in many poor-prognosis melanomas. It is being studied as possible target for a cancer vaccine or immunotherapy. It is a target for some experimental engineered T-cell therapies for myeloma. Lloyd J. Old#Major Discoveries Gnjatic, S; et al. (2006). "NY-ESO-1: review of an immunogenic tumor antigen". Advances in Cancer Research. 95: 1-30. doi:10.1016/S0065-230X(06)95001-5. PMID 16860654. van Rhee, F (15 May 2005). "NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses" (PDF). Blood. 105 (10): 3939-3944. doi:10.1182/blood-2004-09-3707. PMC 1895070 . PMID 15671442. Rapoport, AP; et al. (20 July 2015). "NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma". Nature Medicine. 21 (8): 914-921. doi:10.1038/nm.3910. PMC 4529359 . PMID 26193344. A novel human-derived antibody against NY-ESO-1 ...
results of an open-label, multicenter, phase I/II trial aiming to determine the Maximal Tolerable Dose (MTD) of alemtuzumab consolidation and to evaluate safety and efficacy in CLL patients who responded to second-line fludarabine-based treatment.
Lets hope the FDA make the same decision for MSers in the US. If not there will be a lot of cross border travel of US MSers, who can afford to be treated in Canada, receiving the infusions there. This is not ideal as the monitoring post-alemtuzumab is critical for making sure this drug is used safely. I wonder who will be legally responsible for the monitoring; the treating clinician in Canada or the referring clinician from the US?" ...
Nayak SK, Dillman RO: Use of autologous tumor cells grown in tissue culture for active specific immunotherapy. [Abstract] Proc Am Assoc Cancer Res 34: A-2937, 1993. ...
Lyrics to Niggas by Bird Baby: Yo yo yo yo yo yo / What up you all niggas in the house / Yo yo yo yo yo yo / Holla back holla back / Nigga
Its obvious you dont like private prescriptions as you see this as the beginning of the end for the NHS. However, if you have a patient who you know would benefit from a drug approved by the EMA but NICE have refused to fund, would you point the patient to where they could buy it legally abroad to ensure that they got the proper drug and not some questionable rubbish off the internet; or if they needed infusions like alemtuzumab, would you point them to a reputable clinic or set of clinics where they could get them? Or would this still endanger your principles due to the possible assumption that you got a commercial benefit from the advice?. ReplyDelete ...
he grading system has given opportunity to score much as compared to earlier system but simultaneously setting of question papers within certain framework h
Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patients immune system to attack those cells. Alternatively, in radioimmunotherapy a radioactive dose localizes a target cell line, delivering lethal chemical doses. More recently antibodies have been used to bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses. This is known as immune checkpoint therapy. It is possible to create a mAb that is specific to almost any extracellular/cell surface target. Research and development is underway to create antibodies for diseases (such as rheumatoid arthritis, multiple sclerosis, Alzheimers disease, Ebola and different types of cancers). Immunoglobulin G (IgG) antibodies are large heterodimeric molecules, approximately 150 kDa and are composed of two kinds of polypeptide chain, called the heavy ...
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic ...
0045]The second-generation antibody CC49 was generated against TAG-72 purified from colon cancer. CC49 showed higher binding affinity than B72.3 to TAG-72 in carcinomas including breast, colorectal, ovarian, and lung carcinomas, while CC49 exhibited minimum reactivity with normal tissues. When 125I-CC49 was administered in xenograft models with colon cancer cells LS 174T, the plasma clearance was much faster than B72.3, which results in much higher tumor to normal tissue distribution ratio. For example, the tumor to blood ratio was 18.1, tumor to liver ratio 3.81, tumor to spleen ratio 16.64, tumor to kidney ratio 36.48, and tumor to lung ratio 25.82. In RIGS studies of 300 patients with colorectal cancers, CC49 was able to successfully detect tumors in 86% of patients with primary tumors and 95% of patients with recurrent tumors. In addition, clinical studies of a modified humanized antibody CC49ΔCH2 with a deletion in glycosylation sites of the antibody showed similar results with CC49 in ...
Across many measures, ocrelizumab appears to be in the same league as alemtuzumab (disability progression, relapse rate, lesions), which leads to amazingly high NEDA-3 rates (,80%). The reduction in brain atrophy from OCR appears to be about 25% relative to INFB-1a with a trial that had 75% treatment naive patients. This is roughly in the same league as the two alemtuzumab trials. CARE-MS I (treatment naive) had a 40% drop, and CARE-MS II (prior treatment) had a 25% drop. If you weight that out to compare fairly, maybe alemtuzumab has a 36% drop vs ocrelizumabs 25%. This is a decent numeric difference, but given the variability and complexity of measuring atrophy, its hard to know if this is really material (especially given the other metrics ...
Recent studies have identified new melanoma antigens that are recognised by CD4(+) T cells. Analysis of tumour-specific CD4(+) T-cell responses may lead to the development of optimal anti-cancer vaccines that can induce an orchestrated effort of tumour-specific CD4(+) and CD8(+) T cells in the fight against cancer.
Free resource for searching and exporting immune epitopes. Includes more than 95% of all published infectious disease, allergy, autoimmune, and transplant epitope data.
This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections. This search facility features: flexible search syntax; automatic word stemming and relevance ranking; as well as graphical results.
Sanofi has posted a 26.3% leap in fourth-quarter income, largely because of lower charges relating to multiple sclerosis drug Lemtrada (alemtuzumab), which it snapped up with the purchase of Genzyme in 2011. - News - PharmaTimes
Politsei blokeeris kohaliku aja järgi teisipäeval hommikul kella 7 ajal Kopenhaageni Kastrupi lennujaama 2. terminali, et uurida kahtlast pagasit. Midagi problemaatilist lõpuks ei leitud. - DELFI
匆匆忙忙,一年又过去,快到令人发指,快到来不及总结…这一年,去了一些地方,看过不同的风景,有精彩,有遗憾;这一年,对女儿的陪伴少了些,所以她不听话,可能还是我的
根据电动自行车第三者责任保险条款,在保险期间内,被保险人或其年满16周岁的家庭成员在使用保险电动自行车过程中发生意外事故,致使第三者遭受人身伤亡或财产直接损毁,依法应当由被保险人承担的经济赔偿责任,保险公司按照本保险合同的约定负责赔偿。保险事故发生后,被保险人因保险事故而被提起仲裁或者诉讼的,对应由被保险人支付的仲裁或诉讼费用以及其它必要的、合理的费用,经保险人事先书面同意,保险公司按本保险合同的约定也负责赔偿。 ...
Here we have shown that infectivity of primary isolates from individuals with early HIV infection can be enhanced over 350-fold when opsonised with autologous antibodies and complement, compared with infection in the presence of complement alone. The range of increases in infection are comparable to those reported for dengue virus, a disease in which ADE contributes to pathogenesis during secondary infection by a different serotype and in infants carrying sub-neutralising levels of maternal antibodies [44, 46, 47, 69, 70]. Previous studies using X4-tropic TCLA strains of HIV, or primary isolates opsonised with complement alone, typically showed up to 10-fold increases in infection [25, 28, 36, 41, 42, 66], as we have also confirmed when performing similar experiments. A well-characterised enhancing mAb, 246-D, enhanced infection of the TCLA HIV strain IIIB by up to 3.7-fold in our assay system, whereas the same mAb showed a very modest enhancement of the patient primary isolate MM38.29. The same ...
Although some treatments are now available for multiple sclerosis, better treatments are needed for people with aggressive disease. The need to find agents that can prevent or slow disease progression is particularly challenging and requires a concerted global effort that combines academic and pharmaceutical expertise. Although such partnerships are rare, the story of alemtuzumab has shown, inspirationally, that academic and pharmaceutical prowess can be combined to deliver an agent with real promise. Alemtuzumab, which has been used successfully off label to treat active relapsing-remitting multiple sclerosis, is a humanised monoclonal antibody that targets the CD52 antigen on leucocytes. Not surprisingly, there was therefore an outcry when Genzyme, now a Sanofi company, surrendered the licence for all currently licensed preparations of alemtuzumab, with effect from 8 August 2012, meaning that it will no longer be available as a licensed product in the United Kingdom once existing supplies run ...
latest releases: ✓ UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases ✓ ProBioGens GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals ✓ Advagraf(R) Now Approved Across Europe as a Once-Daily Immunosuppressant in Organ Transplantation
article{Cefai2001Funct-14296, title={Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy}, year={2001}, number={7}, volume={8}, journal={Cell death & differentiation}, pages={687--695}, author={Cefai, Daniel and Schwaninger, Ruth and Balli, Markus and Brunner, Thomas and Gimmi, Claude} } ...
Prolymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor. Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted. Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable. While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant.. ...

CHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS | Free Medical TextbookCHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS | Free Medical Textbook

BAIRD Definition and History Plasma Cell Neoplasms Essential Monoclonal Gammopathy Chronic Cold Agglutinin Syndrome ... GENERAL CONSIDERATIONS Williams Hematology CHAPTER 104 PLASMA CELL NEOPLASMS: GENERAL CONSIDERATIONS STEPHEN M. ... Crisp D, Pruzanski W: B cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 72:915, 1982. ... PLASMA CELL NEOPLASMS. Plasma cell neoplasms are monoclonal tumors comprised of plasma cells and their precursors. All the ...
more infohttps://medtextfree.wordpress.com/2012/01/23/chapter-104-plasma-cell-neoplasms-general-considerations/

IJMS  | Free Full-Text | Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies | HTMLIJMS | Free Full-Text | Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies | HTML

Bispecific antibodies in the IgG format include asymmetric bispecific antibodies and homodimerized bispecific antibodies, all ... Bispecific antibodies can also be used to treat hemophilia A by mimicking the function of factor VIII. Bispecific antibodies ... Bispecific antibodies that can simultaneously bind to cell surface antigens and payloads are a very ideal delivery system for ... Bispecific antibodies that can inhibit two correlated signaling molecules at the same time can be developed to overcome ...
more infohttp://www.mdpi.com/1422-0067/18/1/48/htm

US20110081408A1 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms 
        - Google...US20110081408A1 - Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms - Google...

... the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies ... invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. ... 1) an anti-CXCL13 antibody, a fragment of an anti-CXCL13 antibody, an anti-CXCR5 antibody, or a fragment of an anti-CXCR5 ... 1) an anti-CXCL13 antibody, a fragment of an anti-CXCL13 antibody, an anti-CXCR5 antibody, or a fragment of an anti-CXCR5 ...
more infohttps://patents.google.com/patent/US20110081408A1/en

FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123...FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123...

... the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy ... Antibodies. *FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and ... ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and ... FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123- ...
more infohttps://pipelinereview.com/index.php/2018122270176/Antibodies/FDA-Approves-ELZONRISTM-tagraxofusp-the-First-Treatment-for-Blastic-Plasmacytoid-Dendritic-Cell-Neoplasm-and-First-CD123-Targeted-Therapy.html

Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and...Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and...

... of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms. Rancés ... Monoclonal Antibody. We used 14F7 Mab, produced at the Center of Molecular Immunology (Havana, Cuba) as previously described [ ... A study with specific monoclonal antibodies," Cancer, vol. 65, no. 3, pp. 499-505, 1990. View at Google Scholar ... BCC and SCC are malignant neoplasms arising from the keratinocytes, cells of ectodermal origin that usually show a slower and ...
more infohttps://www.hindawi.com/journals/isrn/2011/848909/

Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to...Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to...

... typing as a tool for a more precise characterization of the origin and differentiation of human neoplasms. ... Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ... "Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ... Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ...
more infohttp://ijp.iranpath.org/article_29938.html

Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. - Oxford Clinical Trial...Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. - Oxford Clinical Trial...

These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia ... antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval ... Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. ... Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. ...
more infohttps://www.ctsu.ox.ac.uk/publications/44127

Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to...Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to...

... typing as a tool for a more precise characterization of the origin and differentiation of human neoplasms. ... "Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ... Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ... Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to ...
more infohttp://ijp.iranpath.org/article_29938_3969.html

Autoimmune encephalitis: a review of diagnosis and treatmentAutoimmune encephalitis: a review of diagnosis and treatment

Key words: encephalitis; antibodies, neoplasm; status epilepticus; anti-N-Methyl-D-Aspartate receptor encephalitis; ... Anti-neuronal antibodies are classified into antibodies against cell surface antigens (CSAab), antibodies against synaptic ... Recently, anti-GlyR antibodies have also been reported in patients with cerebellar ataxia and anti-GAD antibodies and patients ... C) red: CSF from a patient with AMPAR antibodies, green: commercial antibody against the GluA1/2 subunits of AMPARs). (D) Live ...
more infohttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000100041&lng=en&nrm=iso&tlng=en

Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease.Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease.

Antibodies, Monoclonal / therapeutic use*. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use*. Chronic ... 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 3A189DH42V/alemtuzumab ...
more infohttp://www.biomedsearch.com/nih/Alemtuzumab-induced-resolution-refractory-cutaneous/18158955.html

Effect of a mouse mammary tumor virus-derived protein vaccine on primary tumor d :: TNO RepositoryEffect of a mouse mammary tumor virus-derived protein vaccine on primary tumor d :: TNO Repository

Animal · Antibodies, Neoplasm · Female · Immunity, Cellular · Immunization, Secondary · Leukocyte Adherence Inhibition Test · ... The titer of antibodies to tumor cells, as estimated by membrane immunofluorescence, was also higher in the GR strain. In BALB/ ... Two or five additional booster injections with 1 μg protein vaccine had no beneficial effect, although the amount of antibody ... Mammary Neoplasms, Experimental · Mammary Tumor Virus, Mouse · Mice · Mice, Inbred Strains · Vaccination · Viral Proteins · ...
more infohttps://repository.tudelft.nl/view/tno/uuid%3Ad3fa499f-64fe-4d42-9584-8e2d2e40cfc9

T-cell prolymphocytic leukemia: A rare disease in an elderly female.T-cell prolymphocytic leukemia: A rare disease in an elderly female.

Antibodies, Monoclonal / adverse effects, therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / adverse ... 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 0/Antineoplastic Agents; 3A189DH42V/ ...
more infohttp://www.biomedsearch.com/nih/T-cell-prolymphocytic-leukemia-rare/21129072.html

basal cell carcinoma of skin with metastasis diagnosis 2005:2010[pubdate] *count=100 - BioMedLib™ search enginebasal cell carcinoma of skin with metastasis diagnosis 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Skin Neoplasms / surgery. *[MeSH-minor] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antibodies ... Skin Neoplasms / pathology. *[MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm ... Facial Neoplasms / pathology. Lung Neoplasms / secondary. Skin Neoplasms / pathology. *[MeSH-minor] Adult. Carcinoma, Basal ... Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. ...
more infohttp://www.bmlsearch.com/?kwr=basal+cell+carcinoma+of+skin+with+metastasis+diagnosis+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

apocrine adenocarcinoma unspecified site 2005:2010[pubdate] *count=100 - BioMedLib™ search engineapocrine adenocarcinoma unspecified site 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Antibodies, Neoplasm / immunology. Skin Neoplasms / immunology. Skin Neoplasms / pathology. *MedlinePlus Health Information. ... Eyelid Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Parotid Neoplasms / diagnosis. Sweat Gland Neoplasms / ... Breast Neoplasms / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Sweat Gland Neoplasms / diagnosis ... Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / veterinary. *NCI CPTC Antibody Characterization Program. NCI CPTC ...
more infohttp://www.bmlsearch.com/?kwr=apocrine+adenocarcinoma+unspecified+site+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and...Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and...

T1 - Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ... Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ... Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ... Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and ...
more infohttps://mayoclinic.pure.elsevier.com/en/publications/single-antibody-detection-of-t-cell-receptor-%CE%B1%CE%B2-clonality-by-flow

Characterization of the ant ige nie epitope recognized by tumor selective antibody<...Characterization of the ant ige nie epitope recognized by tumor selective antibody<...

Characterization of the ant ige nie epitope recognized by tumor selective antibody. / Rose, I. M.; Denardo, D. L.; Meares, C. F ... Rose, IM, Denardo, DL & Meares, CF 1997, Characterization of the ant ige nie epitope recognized by tumor selective antibody, ... The selcriiviiy of Lym-1 for malignant li-jympliocytns makes this mono clonal antibody a promising randidaic for tho d(li\i ... N2 - The selcriiviiy of Lym-1 for malignant li-jympliocytns makes this mono clonal antibody a promising randidaic for tho d(li ...
more infohttps://ucdavis.pure.elsevier.com/en/publications/characterization-of-the-ant-ige-nie-epitope-recognized-by-tumor-s

Rheumatology - Research Output
     - Mayo ClinicRheumatology - Research Output - Mayo Clinic

Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in ... Neoplasms Mayo Clinic office visit. TNF drugs and rheumatoid arthritis. An interview with Eric Matteson, M.D. Matteson, E. L., ...
more infohttps://mayoclinic.pure.elsevier.com/en/organisations/rheumatology-2/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Farticle&page=12

Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I...Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I...

... or even by staining histologic sections of tumors with antibodies recognizing neuroblastoma cells and cell proliferation. In a ... or even by staining histologic sections of tumors with antibodies recognizing neuroblastoma cells and cell proliferation. In a ... or even by staining histologic sections of tumors with antibodies recognizing neuroblastoma cells and cell proliferation. In a ... or even by staining histologic sections of tumors with antibodies recognizing neuroblastoma cells and cell proliferation. In a ...
more infohttps://moh-it.pure.elsevier.com/en/publications/tumor-regression-and-curability-of-preclinical-neuroblastoma-mode

Find Research Outputs
             - Hungarian ConsortiumFind Research Outputs - Hungarian Consortium

Titre of anti E. coli antibodies in ulcerative colitis. Kovács, A., 1974, In : Digestion. 10, 3, p. 205-209 5 p.. Research ... The role of tumour specific antibody and interferon production in the pathogenesis of Rauscher leukaemia. Tóth, F., Vaczi, L ...
more infohttps://hungary.pure.elsevier.com/en/publications/?format=&page=3112

Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab...Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab...

Antibodies Breast neoplasm Drug therapy Prospective study Treatment outcome This is a preview of subscription content, log in ... Pegram M, Hsu S, Lewis G (1997) Inhibitory effects of combinations of HER2/Neu antibody and chemotherapeutic agents used for ... Adams CW, Allison DE, Flagella K et al (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER ... Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the ...
more infohttps://link.springer.com/article/10.1007%2Fs10147-014-0727-x

農学研究院 - 研究成果
     - 九州大学農学研究院 - 研究成果 - 九州大学

Glycosylation of antibody in a lectin-resistant human hybridoma is insensitive to glucose. Tachibana, H., Ushio, Y. & Murakami ... Epitope in cytochrome C from Candida krusei cross-reacts lung cancer-specific human monoclonal antibody HB4C5. Kawamoto, S., ...
more infohttps://kyushu-u.pure.elsevier.com/ja/organisations/faculty-of-agriculture-6/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Fletter

Michieli, P.<...Michieli, P.<...

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. Cignetto, S., Modica ... Neoplasms Medicine & Life Sciences Growth Medicine & Life Sciences Oncogenes Medicine & Life Sciences ... Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo ...
more infohttps://moh-it.pure.elsevier.com/en/persons/paolo-michieli

Vascular NeoplasmsVascular Neoplasms

... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or ... Neoplasm Proteins. 45. + 4. DNA, Neoplasm. 40. + 5. Antibodies, Neoplasm. 34. + 6. Ethylnitrosourea. 31. + ...
more infohttps://lookfordiagnosis.com/results.php?symptoms=Vascular+Neoplasms&lang=1&parent=%2F&mode=F&therapy_ap=1
  • All the differentiated cells within such a neoplasm produce the same whole immunoglobulin chain or chain fragment. (wordpress.com)
  • Nakopoulou L, Stefanaki k, Janinis J, Mastrominas M. Immunohistochemical Expression of placental alkaline phosphatase and vimentin in Epithelial Ovarian Neoplasms. (iranpath.org)
  • The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. (google.com)
  • Two or five additional booster injections with 1 μg protein vaccine had no beneficial effect, although the amount of antibody measured was increased after boosting. (tudelft.nl)
  • In contrast, the antibodies appeared only after the third to sixth vaccination and the plateau appeared after the fourth to eighth cycle in patients vaccinated with the CHP-HER2 vaccine alone over the first four cycles. (edu.au)
  • SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older, in both treatment-naïve and previously-treated populations. (pipelinereview.com)
  • The antibodies became detectable after the second or third vaccination and reached plateau levels after the third or fourth cycle in patients vaccinated with CHP-HER2 plus GM-CSF. (edu.au)
  • The CSAab (i.e., anti-NMDAR antibodies) target molecules involved in neurotransmission leading to neuronal dysfunction 7 . (scielo.br)
  • More recently antibodies have been used to bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses. (wikipedia.org)
  • The description of an antibody specific for one of two mutually exclusive T-cell receptor (TCR) β-chain constant regions (TRBC1) provide an opportunity to facilitate the detection of clonal TCRαβ T-cells based on TRBC-restriction. (elsevier.com)
  • Background: The diagnosis of T-cell neoplasms is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. (elsevier.com)
  • Conclusion: Inclusion of a single anti-TRBC1 antibody into a diagnostic T-cell flow cytometry panel facilitates the rapid identification of T-cell neoplasms, in addition to small monotypic CD8-positive subsets of uncertain significance. (elsevier.com)
  • The Fab fragments contain the variable domains, which consist of three antibody hypervariable amino acid domains responsible for the antibody specificity embedded into constant regions. (wikipedia.org)
  • The antibodies block high affinity interactions leading to the growth or migration of cancer cells. (google.com)
  • These antibodies have: a short half-life in vivo (due to immune complex formation), limited penetration into tumour sites and inadequately recruit host effector functions. (wikipedia.org)
  • Immunohistochemical Characterization of Normal Ovary and Common Epithelial Ovarian Neoplasm with a Monoclonal Antibody to Cytokeratin and Vimentin', Iranian Journal of Pathology , 13(1), pp. 23-29. (iranpath.org)
  • After adjustment for smoking and other sexually transmitted diseases, antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval 1.6-15.7)), but the numbers were too small for drawing conclusions as to the sexually transmitted diseases with which cervical cancer is most specifically associated. (ox.ac.uk)